Literature DB >> 31068407

Opinions of Primary Care Clinicians and Psychiatrists on Monitoring the Metabolic Effects of Antipsychotics.

Christina Mangurian1, Aishat Giwa2, Erin Brosey2, Martha Shumway2, James Dilley2, Elena Fuentes-Afflick2, Eliseo J Pérez-Stable2, Dean Schillinger2.   

Abstract

OBJECTIVE: Although people with severe mental illness (SMI) have high rates of diabetes and other metabolic disorders, adherence to recommended screening guidelines is low. This study aimed to compare primary care clinicians' and psychiatrists' attitudes toward metabolic monitoring and treatment of patients with SMI.
METHODS: Primary care clinicians and psychiatrists within 1 large urban integrated public health system were recruited to participate in this online survey study. Multivariate logistic regression analyses were used to examine if clinician characteristics were associated with attitudes or perceived barriers toward metabolic monitoring and treatment.
RESULTS: Response rates were 77% (164/214) of primary care providers and 69% (56/81) of psychiatrists completing the survey. There were no significant differences in age or race/ethnicity between provider groups, although primary care clinicians were more likely to be women when compared with the psychiatrists (69% vs 39%, P < .001). Psychiatrists were more likely than primary care clinicians to believe that psychiatrists should conduct metabolic monitoring even if patients had a primary care provider (80% vs 60%, P = .011) However, fewer psychiatrists than primary care clinicians believed that psychiatrists should treat identified cardiometabolic abnormalities (15% vs 42%, P < .001).
CONCLUSION: Systemic problems with care coordination and these varying expectations likely contribute to poor cardiometabolic outcomes in this vulnerable population. © Copyright 2019 by the American Board of Family Medicine.

Entities:  

Keywords:  Diabetes Mellitus; Logistic Regression; Mental Disorders; Mental Health; Metabolic Diseases; Primary Health Care; Psychiatry; Public Health; Surveys and Questionnaires; Vulnerable Populations

Mesh:

Substances:

Year:  2019        PMID: 31068407      PMCID: PMC7213492          DOI: 10.3122/jabfm.2019.03.180176

Source DB:  PubMed          Journal:  J Am Board Fam Med        ISSN: 1557-2625            Impact factor:   2.657


  32 in total

1.  Severe mental illness and risk of cardiovascular disease.

Authors:  John W Newcomer; Charles H Hennekens
Journal:  JAMA       Date:  2007-10-17       Impact factor: 56.272

Review 2.  Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders--a systematic review and meta-analysis.

Authors:  Alex J Mitchell; Davy Vancampfort; Kim Sweers; Ruud van Winkel; Weiping Yu; Marc De Hert
Journal:  Schizophr Bull       Date:  2011-12-29       Impact factor: 9.306

3.  Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline.

Authors:  Henry A Nasrallah; Jonathan M Meyer; Donald C Goff; Joseph P McEvoy; Sonia M Davis; T Scott Stroup; Jeffrey A Lieberman
Journal:  Schizophr Res       Date:  2006-08-01       Impact factor: 4.939

4.  American association of clinical endocrinologists and american college of endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015.

Authors:  Yehuda Handelsman; Zachary T Bloomgarden; George Grunberger; Guillermo Umpierrez; Robert S Zimmerman; Timothy S Bailey; Lawrence Blonde; George A Bray; A Jay Cohen; Samuel Dagogo-Jack; Jaime A Davidson; Daniel Einhorn; Om P Ganda; Alan J Garber; W Timothy Garvey; Robert R Henry; Irl B Hirsch; Edward S Horton; Daniel L Hurley; Paul S Jellinger; Lois Jovanovič; Harold E Lebovitz; Derek LeRoith; Philip Levy; Janet B McGill; Jeffrey I Mechanick; Jorge H Mestman; Etie S Moghissi; Eric A Orzeck; Rachel Pessah-Pollack; Paul D Rosenblit; Aaron I Vinik; Kathleen Wyne; Farhad Zangeneh
Journal:  Endocr Pract       Date:  2015-04       Impact factor: 3.443

5.  The STRIDE weight loss and lifestyle intervention for individuals taking antipsychotic medications: a randomized trial.

Authors:  Carla A Green; Bobbi Jo H Yarborough; Michael C Leo; Micah T Yarborough; Scott P Stumbo; Shannon L Janoff; Nancy A Perrin; Greg A Nichols; Victor J Stevens
Journal:  Am J Psychiatry       Date:  2014-10-31       Impact factor: 18.112

6.  Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial.

Authors:  René S Kahn; W Wolfgang Fleischhacker; Han Boter; Michael Davidson; Yvonne Vergouwe; Ireneus P M Keet; Mihai D Gheorghe; Janusz K Rybakowski; Silvana Galderisi; Jan Libiger; Martina Hummer; Sonia Dollfus; Juan J López-Ibor; Luchezar G Hranov; Wolfgang Gaebel; Joseph Peuskens; Nils Lindefors; Anita Riecher-Rössler; Diederick E Grobbee
Journal:  Lancet       Date:  2008-03-29       Impact factor: 79.321

7.  Primary care providers' views on metabolic monitoring of outpatients taking antipsychotic medication.

Authors:  Christina Mangurian; Funmi Giwa; Martha Shumway; Elena Fuentes-Afflick; Eliseo J Pérez-Stable; James W Dilley; Dean Schillinger
Journal:  Psychiatr Serv       Date:  2013-06       Impact factor: 3.084

8.  Premature Mortality Among Adults With Schizophrenia in the United States.

Authors:  Mark Olfson; Tobias Gerhard; Cecilia Huang; Stephen Crystal; T Scott Stroup
Journal:  JAMA Psychiatry       Date:  2015-12       Impact factor: 21.596

9.  The gap in life expectancy from preventable physical illness in psychiatric patients in Western Australia: retrospective analysis of population based registers.

Authors:  David Lawrence; Kirsten J Hancock; Stephen Kisely
Journal:  BMJ       Date:  2013-05-21

10.  Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states.

Authors:  Craig W Colton; Ronald W Manderscheid
Journal:  Prev Chronic Dis       Date:  2006-03-15       Impact factor: 2.830

View more
  3 in total

1.  Yonder: Parkinson's disease, dietary education, antipsychotic medications, and genomic results.

Authors:  Ahmed Rashid
Journal:  Br J Gen Pract       Date:  2019-10-31       Impact factor: 5.386

Review 2.  Cardiovascular disease in patients with severe mental illness.

Authors:  René Ernst Nielsen; Jytte Banner; Svend Eggert Jensen
Journal:  Nat Rev Cardiol       Date:  2020-10-30       Impact factor: 32.419

3.  Monitoring of Adverse Drug Reaction-Related Parameters in Children, Youth, and Young Adults Prescribed Antipsychotic Drugs by General Practitioners.

Authors:  Lenneke Minjon; Els van den Ban; Marloes T Bazelier; Arief Lalmohamed; Toine C G Egberts; Eibert R Heerdink
Journal:  J Child Adolesc Psychopharmacol       Date:  2021-10-07       Impact factor: 2.576

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.